Labdane diterpenoids have a broad spectrum of biological activities including antibacterial, antiviral and anti-inflammatory properties. However, little is known about their possible role in the apoptotic cell death machinery. Here, we report that hispanolone derivatives, a group of labdane diterpenoids, induce apoptosis in different tumor cell lines by activating caspase-8 with subsequent participation of mitochondrial signaling. Activation of caspase-8 by hispanolone derivatives was followed by a decrease in mitochondrial membrane potential, the release of apoptotic factors from mitochondria to the cytosol, and activation of caspases-9 and 3. Hispanolone derivatives also led to a time-dependent cleavage of Bid. Inhibition of caspase-8 abrogated these processes, suggesting that the death receptor pathway has a critical role in the apoptotic events induced by hispanolone derivatives. In addition, silencing death receptors with small interfering RNA s or pretreating cells with neutralizing antibodies to Fas ligand, tumor necrosis factor receptor 1 (TNF-R1), and TNF-a receptor 2 (TRAIL) inhibited diterpenoid-induced apoptosis, revealing it to be dependent on these death receptors. Interestingly, hispanolone derivatives had no effect on non-tumor cells. Consistently, in vivo bioluminescence imaging corroborates this antineoplasic effect, as hispanolone derivatives significantly decrease cancer growth in tumor xenograft assays. These data demostrate the antitumoral effects of hispanolone derivatives and provide relevant preclinical validation for the use of these compounds as potent therapeutic agents in cancer treatment.
INTRODUCTION
Terpenoids are the largest and most abundant class of natural compounds. They are extracted from higher plants, mosses, liverworts, algae and lichens, and are also present in insects, microbes or marine organisms. Labdanes, which are bicyclic diterpenoids, have a broad spectrum of biological activities including antibacterial, antiviral and anti-inflammatory actions. 1 We recently reported that hispanolone derivatives, a group of labdane diterpenoids, exert anti-inflammatory effects by inhibiting the activation of nuclear factor-kB (NF-kB); 2 however, to date there have been no reports characterizing the possible interaction of hispanolone derivatives with the apoptotic cell death machinery.
Apoptosis is an evolutionarily conserved program cell death process that is essential for normal tissue homeostasis and participates in the elimination of potentially dangerous cells, including the precursors of tumor cells. 3 Two main activation pathways have been identified, termed the extrinsic and intrinsic pathways. 4 The extrinsic pathway is initiated at the plasma membrane by activation of cell surface death receptors such as Fas/CD95, tumor necrosis factor receptor 1 (TNF-R1) and TNF-a receptor 2 (TRAIL). Ligand-activated death receptors recruit the adaptor molecule Fas-associated death domain protein, which in turn recruits and activates an initiator enzyme, usually caspase-8, in the death-inducing signaling complex. 5 Processed caspase-8 activates downstream apoptotic effectors such as caspases 3, 6 and 7. 6 The intrinsic pathway is mediated by mitochondria, and involves the release of proapoptotic factors such as cytochrome c from the intramembrane space to the cytosol. Once released, cytochrome c and dATP bind to apoptotic proteinase-activating factor-1. This complex, together with adenine nucleotides, promotes the autoactivation of procaspase-9 to caspase-9 followed by the activation of the effector caspases 2, 3, 6, 8 and 10. 7 Release of apoptosis-related proteins from mitochondria is controlled by proapoptotic members of the Bcl-2 family such as Bid. Caspase-8 can process Bid to generate the active truncated form, providing a link between the extrinsic and intrinsic pathways. 8 In this study, we have evaluated the proapoptotic potential of the natural labdane diterpenoids hispanolone (T1) 9 and galeopsin (T9), 10 together with a series of nine synthetic hispanolone derivatives (T2 --T8, T10 and T11). Our results reveal that two of these compounds, T2 and T6, promote apoptosis through the death receptor pathway. The caspase-8 inhibitor Ac-IETD-CHO dramatically reduced apoptosis, demonstrating that caspase-8 is the upstream initiator enzyme. The mitochondrial pathway was subsequently activated, with loss of DCm, cytochrome c release and activation of caspases 9 and 3. Moreover, neutralizing antibodies against TRAIL-R2, TNF-R1 and Fas ligand and gene silencing of these receptors also effectively inhibited cell death. Relevantly for clinical application, treatment with hispanolone derivatives significantly inhibited the tumor growth induced by B16F10 and ID8 cells implanted in NOD SCID mice. Thus, our finding shows that hispanolone derivatives may offer a new promising therapeutic agent for cancer.
RESULTS

Induction of apoptosis by labdane diterpenoids
The terpenoids selected for this study have been previously described; 2 and are the natural labdane diterpenoids hispanolone (T1) and galeopsin (T9) and a series of nine hispanolone derivatives (T2 --T8, T10 and T11). To investigate the apoptotic potential of these compounds, RAW 264.7 (mouse leukemic macrophagic cell line), Jurkat (human acute T-cell leukemia) and THP-1 (human acute monocytic leukemia cell line) cells were treated for 24 h with 50 mM of each compound (Figure 1a ). T2 and T6 were the most effective terpenoids, reaching the levels of apoptosis around 88. 2 Table 1) . Given their stronger apoptotic action, T2 and T6 were the principal compounds tested in subsequent experiments. When indicated, T7 was used as an internal negative control.
To discard possible induction of necrosis, we measured LDH release from RAW 264.7 cells treated with T6 or T7. Despite that T6 treatment reduced the number of viable cells, as measured by flow cytometry, this terpenoid did not induce necrosis over the concentration range studied (Supplementary Figure 1) . Compound T7 used as control did not alter cell viability in this assay.
Expression of apoptosis-related genes in cells treated with hispanolone derivatives To identify genes differentially expressed in response to hispanolone derivatives, cells were incubated with T6 (25 mM for 2, 4 and 8 h, respectively), and RNA isolated from treated and control cells was hybridized to a RT 2 Profiler PCR Array. Genes that exhibited at least 2-fold difference in expression were considered T6-responsive. Employing this criterion, we identified 45 genes similarly expressed in control and treated cells (data not shown), four genes downregulated and 35 genes upregulated (Supplementary Table 2 ). Upregulated events included a group of signal transduction genes involved in the induction of apoptosis such as the death receptors TNF-R1, TRAIL-R2 and Fas, as well as the proapoptotic members of the Bcl-2 family, Bak, Bid and Bax. In contrast, antiapoptotic molecules like Bcl-2 were downregulated. In order to validate the data obtained in the RT 2 Profiler PCR Array, we performed quantitative PCR showing similar ratio of the gene expression ( Figure 1c ).
Diterpenoids activate caspase-8 and the mitochondrial pathway Given the finding that T6 upregulates the death receptors expression, we next investigated its ability to modify other key events in apoptosis signaling, such as caspase activation and mitochondrial signaling. Treatment of RAW 264.7 and Jurkat cells with T6 induced caspase-8 activation, as determined fluorometrically using Ac-IETD-AMC (Figure 2a ).
Active caspase-8 can trigger the mitochondrial apoptotic pathway by cleaving Bid, originating the truncated form that induces the release of cytochrome c from mitochondria. Treatment of RAW 264.7 and Jurkat cells with T6 (25 mM) induced cleavage of Bid in a time-dependent manner, as shown by western blot in the Figure 2b . Moreover, protein analysis confirmed the reduction in the expression of the anti-apoptotic protein Bcl-2 ( Figure 2b ). T6-induced Bid activation was accompanied by increment in cytosolic cytochrome c (Figure 2b ). To determine whether truncated Bid alters mitochondrial signaling, we monitored DC m by flow cytometry using TMRM labeling, as measurement of the permeability of the organelle. As shown in Figure 2c , RAW 264.7 and Jurkat cells treated with T6 induced a collapse in DC m . T7 was used as control. T6-induced Bid processing and mitochondrial membrane depolarization were accompanied by upregulation in the enzymatic activities of caspases 9 and 3 (Figures 2d and e) . These data thus demonstrate that the selected hispanolone derivative induces apoptosis via the activation of caspase-8, which activates the extrinsic pathway, and induction of mitochondrial apoptotic events through the action of truncated Bid.
Inhibition of caspase-8 prevents hispanolone derivative-induced apoptosis To confirm the primary role of caspase-8 activity in diterpenoidinduced apoptosis, we tested the ability of the caspase-8 inhibitor IETD-CHO to block this effect. Pretreatment of cells with IETD-CHO completely inhibited T6-induced caspase-8 activation and apoptosis (Figure 3a) . Moreover, IETD-CHO also inhibited the mitochondrial apoptotic pathway. The caspase-8 inhibitor impaired Bid cleavage, the reduction in the expression of Bcl-2 and Bcl-xl, and the release of cytochrome c from mitochondria (Figure 3b) , and prevented the collapse of DC m (Figure 3c ). Consistently, there was a corresponding blockade of the activation of the downstream effectors caspase-9 and 3 ( Figure 3d ). Similar results were obtained in Jurkat cells (data not shown).
Blockage of death receptors abrogates apoptosis induced by hispanolone derivatives As T6 increases the mRNA expression of Fas, TNF-R1 and TRAIL-R2, next we examined the regulation at the protein level of these receptors. A time-course experiment determined that addition of 25 mM T6 to Jurkat cells progressively increased Fas, TNF-R1 and TRAIL-R2 levels up to 24 h (Figure 4a ). Accordingly, flow cytometry analysis also showed an enhanced surface expression of these receptors after T6 treatment (Supplementary Figure 2) .
Next, we used neutralizing antibodies to determine the biological significance of the upregulated death receptors signaling in the T6-induced apoptosis. Pre-treatment with neutralizing antibodies to Fas ligand, TRAIL-R2 and TNF-R1 inhibited T6-induced apoptosis by 66.35, 60.28 and 43.45% in RAW264.7 cells and 47.2, 56.4 and 39.8% in Jurkat cells, respectively. Moreover, a combination of all three antibodies completely prevented diterpenoid-induced apoptosis (Figure 4b ). Light microscopy corroborated this result revealing inhibition of the typical apoptotic morphological changes (Figure 4d ). The neutralizing antibodies also inhibited caspase-8 activity (Figure 4c ), as well as Bid cleavage and the reduction in Bcl-2 levels (Figure 4e ), confirming that diterpenoid-induced apoptosis is initiated via activation of death receptor pathways. To further confirm the critical role of these receptors on T6-induced apoptosis, RNA interference technology was applied. Jurkat cells were transfected with small interfering RNAs (siRNAs) against Fas, TRAIL-R2 and TNF-R1, and 24 h after transfection cells were treated with T6. siRNAs efficiency was evaluated by western blot (Figure 4f) . Suppression of Fas, TRAIL-R2 and TNF-R1 significantly blocked the apoptosis induced by T6 (43.01%, 67.03% and 40.93%, respectively) (Figure 4g ). Similar results were obtained with RAW 264.7 cells (data not shown). These results collectively indicate that upregulation of death receptors is important for T6-induced apoptosis.
Non-tumor cells are more resistant to T6-induced apoptosis To examine the effects of T6 on non-tumor cells, we used primary cultures of peritoneal macrophages obtained from thioglycolateinjected mice. Peritoneal macrophages or RAW 264.7 cells were stimulated for 24 h with a range of concentrations of T6 or T7, and apoptosis and caspase activation were determined ( Figure 5a ). T6 (50 mM) induced apoptosis and activated caspase-8, 9 and 3 in RAW 264.7 cells. However, even at this high dose, apoptosis was slightly induced in peritoneal macrophages (34.77%) compared with RAW 264.7 cells (95.8%). Moreover, the IC 50 of T6 in RAW 264.7 cells did not induce apoptosis in peritoneal macrophages.
To further examine the effect of T6 on normal cells, we compared the cytotoxicity of T6 on leukemic cells and freshly isolated peripheral blood lymphocytes (PBLs). As shown in Figure 5b , the percentage of apoptosis of Jurkat and REH cells was much higher than that on PBLs after T6 treatment. In addition, we also found that percentage of caspase-3 activity in PBLs was much lower comparing with leukemic cells (Figure 5b ). These data T1  T2  T3  T4  T5  T6  T7  T8  T9  T10 T1  T2  T3  T4  T5  T6  T7  T8  T9  T10 T1  T2  T3  T4  T5  T6  T7  T8  T9  T10 thus suggest that transformed cells are more susceptible to apoptosis elicited by T6 than normal cells, providing evidence for the potential use of the selected hispanolone derivatives as antitumor agents.
T2 and T6 exert greater cytotoxic effect than andrographolide Andrographolide is the main labdane diterpenoid present in Andrographis paniculata, and induces apoptosis in several tumor cell lines. 11 --13 To compare the antitumor potential of andrographolide vs T2 and T6, we treated different tumor cell lines with the three compounds over a range of concentrations. As shown in Figure 5c , T2 and T6 induced higher apoptosis rates than andrographolide in all tested lines. Thus, IC 50 values of andrographolide were 100 mM, 75 mM, 80 mM and 90 mM for RAW 264.7, Jurkat, B16F10 and ID8 cells, respectively, whereas T2 and T6 showed IC 50 values in a range of 15 mM for RAW 264.7 and Jurkat cells, and 40 mM for B16F10 and ID8 cells.
Toxicity studies of T6 in mice We examined the toxicity profile of T6 in C57BL/6 mice. To this end, 30 8-week-old mice were treated with a daily intraperitoneally (i.p.) dose of T6 at 30 mg/kg/day for 1 week. Control mice (n ¼ 10) were treated with vehicle alone. All T6-treated mice remained healthy and gained weight throughout the 30-day observation period with no evidence of morbidity (Supplementary Figure 3b) . Blood tests done on days 7, 15 and 30 did not suggest any significant systemic toxicity. In particular, T6 did not cause: (i) anemia, neutropenia, lymphopenia, or thrombocytopenia suggestive of hematologic toxicity (Supplementary Figure 3c) ; (ii) elevations of creatinine suggestive of renal toxicity (Supplementary Figure 3d ); or (iii) elevations of alanine aminotransferase and aspartate aminotransferase suggestive of hepatotoxicity (Supplementary Figure 3d) . Moreover, no toxicity was found in any of the organs from 20 T6-treated mice (or 10 vehicle-treated control mice) killed at 15 days (data not shown) or 30 days (Supplementary Figure 3e) . Thus, T6 treatment was nontoxic and was not associated with any subclinical systemic toxicity.
Evaluation of T6 as anticancer therapy in animal models
In an effort to determine whether T6 could inhibit in vivo tumor growth, luc-B16F10 cells were treated for 15 min in vitro with T6 (25 mM) or dimethyl sulfoxide (DMSO) (vehicle) and subsequently transplanted into the subcutaneously (s. volume of vehicle alone were administered as described in material and methods. Again, tumor growth was inhibited in T6-treated mice with 52% reduction in tumor growth, and 49% reduction in luciferase activity compared with the control group (Figure 6b) . Finally, luc-ID8 cells were i.p. injected to NOD SCID mice and T6 or vehicle was administered. In vivo luciferase analysis of the tumor cells corroborates the T6-mediated antitumoral activity (Figure 6c) . In order to determine whether the inhibition of tumor growth is mediated by T6-induced apoptosis, we evaluated caspase-3 activity in extracts obtained from B16F10 and ID8-induced tumors. Caspase-3 activity was increased in cancer tissues from T6-treated animals, whereas no activity was observed in DMSO-injected animals (Figures 6b and c) . Thus, tumor weight measurements and luciferase activity evaluation indicate that T6 inhibits tumor progression. Collectively, all these results propose diterpenoid T6 as a new drug for cancer therapy.
DISCUSSION
Terpenoids are present in all organisms but are especially abundant in plants, with 430 000 compounds identified. So far several terpenoids, including diterpenes, triterpenes and sesquiterpenes, have been found to have excellent anti-inflammatory and antineoplastic potential. 2,14 --17 Although the mechanisms of action of these compounds have not been fully characterized, their ability to suppress tumor proliferation and to induce apoptosis may represent an important means of chemoprevention.
Apoptosis, or programmed cell death, is a highly organized physiological process that functions to eliminate damaged or abnormal cells. In the present study, we have described the proapoptotic action of hispanolone derivatives in tumor cells. To recapitulate the essence of our findings, selected hispanolone derivatives T2 and T6 induce: (1) apoptosis in a panel of human and mouse tumor cell lines; (2) caspase-8 activation; (3) processing of the proapoptotic Bcl-2-related protein Bid; (4) activation of the mitochondrial apoptotic pathway with a significant decrease in DC m ; (5) release of cytochrome c to the cytosol and (6) activation of caspase-9 and 3. The observed effects of hispanolone derivatives were abrogated completely by the specific caspase-8 inhibitor Ac-IETD-CHO, demonstrating that caspase-8 is the upstream initiator enzyme. With regard to mechanisms, hispanolone derivatives were found to trigger marked mRNA and protein expression of the death receptors Fas, TNF-R1 and TRAIL. Interestingly, blockage of death receptor pathway with neutralizing antibodies or gene silencing effectively inhibited cell death.
Taken together, these observations illustrate the involvement of the death receptor pathway in hispanolone derivatives-induced apoptosis and suggest the possible clinical use of these derivatives to selectively induce apoptosis in tumor cells. Other natural products have been shown to induce apoptosis via this pathway, highlighting death receptors like one of the most attractive targets for the treatment of cancer. 12, 18, 19 For example, TRAIL receptors represent a promising candidate for cancer treatment because of their ability to be toxic to human tumor cells in vitro and in vivo, whereas they have a more limited effect on normal cells. 20, 21 Of particular interest in this regard is our finding that the labdane diterpenoid T6 present a stronger proapoptotic action on tumor cells than on primary cell cultures or freshly isolated PBLs. This selective T2-, T6-apoptosis for transformed cells requires further study, but might indicate a greater resistance of normal cells to apoptosis than tumor cells, and suggests a promising future for these compounds as therapeutic agents. In addition, T6 was very well tolerated in vivo without any obvious toxicity. Thus, nor mortality was observed in T6-injected mice and neither significant changes in body weight, hematological and biochemical parameters and histopathological analyses were found.
Natural products have been investigated as potential sources of novel anticancer drugs for decades. 22 However, the genetic complexity of human cancers calls for refocused efforts to develop new multifunctional, rather than monofunctional, drugs to be used either for prevention or treatment. In this regard, synthetic oleanane triterpenoids have recently been shown to have profound effects on inflammation and tissue redox state, as well as being potent anti-proliferative and pro-apoptotic agents. 17 Other studies have shown that inhibition of NF-kB potentiates the efficacy of the antitumor effects of ionizing radiation and some chemotherapeutic compounds. 23, 24 NF-kB is a transcription factor whose activity is required for the induction of 4150 genes involved in cell growth, differentiation and apoptosis. Recent data indicate that some terpenoids, including labdane diterpenes, kaurane diterpenes and sesquiterpenes, inhibit NF-kB signaling.
11,25 --28 Among them, andrographolide, a labdane diterpenoid isolated from a traditional herbal medicine Andrographis paniculata, not only possess potent anti-inflammatory activity but also has been described to induce apoptosis in human cancer cells via activation of caspase-8. 12 These effects are similar to those described for the selected hispanolone derivatives T2 and T6. Indeed, we have recently reported that hispanolone derivatives inhibit NF-kB signaling in macrophages, by directly binding to and inhibiting its kinase activator IKKb. 2 The mechanism is thought to involve the ability of a,b-unsaturated carbonyl groups in labdane diterpenoids to react with cysteine sulfhydryl groups in IKK through Michael-type addition. 2 This inhibition of NF-êB activation by hispanolone derivatives, through the resulting downregulation of antiapoptotic genes, may augment their activation of caspase-8. Interestingly, when we have compared the effects of hispanolone derivatives with andrographolide, T2 and T6 were both more potent inducers of apoptosis than andrographolide, suggesting that hispanolone derivatives could be promising anticancer agents.
Further support for this notion comes from in vivo experiments. Hispanolone derivative T6 was well tolerated and induced a growth inhibition in tumor xenografts. Moreover, an increase in caspase-3 activity was observed in tumors treated with T6. These promising results also emphasize the potential therapeutic value of hispanolone derivatives in human cancer treatment. In summary, hispanolone derivatives T2 and T6 are able to induce tumor apoptosis by activating the death receptor pathway; moreover, although most chemotherapeutic agents are limited to proapoptotic effects, hispanolone derivatives also inhibit the NF-kB pathway. Thus, the novel proapoptotic biological activity of hispanolone derivatives provides valuable knowledge for further investigation, and an excellent base from which to develop new chemotherapeutic drugs.
MATERIALS AND METHODS Materials
Terpenoids (T1 --T11) were obtained as previously described.
2,9,10 Western blot reagents were from GE Healthcare (Pittsburgh, PA, USA). Antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Abcam (Cambridge, MA, USA), BD Biosciences (San Jose, CA, USA), Cell Signaling (Danvers, MA, USA), and R&D Systems (Abingdon, UK). Fluorescent probes for caspase activity were from BD Biosciences (San Jose, CA, USA), and CaspGlow was from BioVision (Milpitas, CA, USA). Culture media were from Lonza (Basel, Switzerland). Ligand stocks, including terpenoids, were dissolved in DMSO and subsequently diluted in PBS before use. siRNAs were purchased from Santa Cruz Biotechnology. The RT 2 Profiler PCR Array was from SuperArray Bioscience (Frederick, MD, USA).
Cell culture conditions RAW 264.7, Jurkat, HT-29, REH and THP-1 cells were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). B16F10 cells were a gift from Dr S Alemany and ID8 cells were a gift from Dr K Roby. For culture, RAW 264.7, Jurkat, REH and THP-1 were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), L-glutamine and antibiotics. HT-29 and B16F10 cells were maintained in DMEM supplemented with 10% FBS, L-glutamine and antibiotics. ID8 cells were maintained in DMEM supplemented with 4% FBS and antibiotics, insulin (5 mg/ml) transferring (5 mg/ml) and sodium selenite (5 ng/ml). All cell lines were mycoplasma tested and kept frozen under liquid nitrogen until resuscitated for use.
Preparation of elicited peritoneal macrophages
Pathogen-free C57BL/6 mice were injected i.p. with 1 ml sterile 10% (w/v) thioglycollate broth. After 4 days, peritoneal macrophages were prepared as previously described. 29 
Isolation of PBLs
PBLs were isolated from healthy volunteers by Ficoll --Hypaque gradient. The cells were washed with PBS twice and then suspended in complete RPMI 1640 with 10% FBS. The viability of the isolated lymphocytes was measured by trypan blue exclusion assay and found to be about 99%.
Flow cytometry analysis of apoptosis and necrosis
After treatment with the appropriate stimuli, cells were stained with 0.005% (w/v) propidium iodide (PI) and annexin V-FITC as recommended by the manufacturer (BD Biosciences), being immediately analyzed in a FACSCanto II flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA). 10 000 events were counted by flow cytometry and an increase in the percentage of annexin-V-positive cells indicates increased apoptosis.
Cytosolic extracts and western blot
Cytosolic extracts were prepared as previously described. 30 Protein content was estimated by the Bio-Rad protein assay. Protein extracts were subjected to SDS --PAGE (10 --15% gels) and blotted onto polyvinylidene difluoride membranes, which were incubated with the following antibodies: anti-b-actin, anti-Bid, anti Bcl-xl, anti-Bcl-2 (all from Santa Cruz Biotechnology), anti-TNF-R1, anti-Fas (R&D systems), anti-TRAIL-R2 (Abcam) and anti-cytochrome c (BD Biosciences). After incubation with HRPconjugated secondary antibody, protein bands were revealed with an enhanced chemiluminescence kit (GE Healthcare). b-actin was used as a loading control.
Assessment of mitochondrial depolarization
To detect changes in DCm, diterpenoid-stimulated cells were harvested and stained (30 min, 37 1C) with tetramethylrhodamine ethyl ester (TMRE; Molecular Probes, Carlsbad, CA, USA), a lipophilic cationic fluorochrome that selectively stains mitochondria that have an intact electrochemical gradient. Cells were analyzed for TMRE fluorescence on a FACSCanto II flow cytometer.
Caspase assays
The activities of caspase-3, 8 and 9 were determined fluorimetrically in cytosolic protein extracts, using the substrates Ac-DEVD-AMC, Ac-IETD-AMC and Ac-LEHD-AMC, respectively, according to the supplier's instructions (BD Biosciences). Alternatively, caspase-8 activity was measured by flow cytometry of living cells, using the CaspGLOW Fluorescein caspase-8 kit according to the supplier's instructions (BioVision).
Gene expression profile
Total RNA was extracted from diterpenoid-treated cells with Trizol reagent (Invitrogen). Expression of apoptotic genes was evaluated with the mouse RT 2 Profiler PCR Apoptosis Array (SuperArray Bioscience). Briefly, 2 mg of RNA were used for cDNA synthesis with RT 2 First Standard kit (SuperArray Bioscience). The mouse apoptosis PCR array was performed according to the manufacturer's protocol, using the Profiler PCR Array System and the SYBR Green/Fluorescein qPCR master mix (SuperArray Bioscience) on an ABI7900 sequence detector (Applied Biosystems). Gene expression was compared with the web-based software package for the PCR Array System (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php); this software automatically performs all DDCt-based fold-change calculations from the specific uploaded raw threshold cycle data.
RNA analysis and quantitative PCR
Total RNA was isolated from cells and mouse tissues with Trizol reagent (Invitrogen). Quantitative PCR (SYBRgreen) analysis was performed with an ABI7900 sequence analyzer as described. 29 Each sample was run in duplicate, and all samples were analyzed in parallel for the expression of the housekeeping gene 36B4 (acidic ribosomal phosphoprotein P0), which was used as an endogenous control for normalization of the expression level of target genes. Fold induction was determined from mean replicate values. Primer sequences are available on request.
Treatment of cells with neutralizing antibodies to death receptors
Cells were pretreated with 20 mg/ml of neutralizing antibodies raised against Fas ligand, TNF-R1, or the extracellular domains of TRAIL-R2 (R&D Systems), either separately or in combination, for 1 h before stimulation for 6 h with 25 mM of the selected diterpenoid.
Small interfering RNA Scrambled (sc-44230) and specific short interfering RNAs (siRNA) to either Fas (sc-29311), TNF-R1 (sc-29507) or TRAIL-R2 (DR5 sc-40237) were from Santa Cruz Biotechnology. Jurkat cells were transfected with siRNA oligos by electroporation (AMAXA, Walkersville, MD, USA). Jurkat cells were transfected with 50 nM Fas siRNA, 50 nM TNF-R1 siRNA, 50 nM TRAIL-R2 siRNA and 100 nM scrambled sequence, which served as a control. The depletion of the respective death receptors was determined by western blot analysis.
In vivo tumor progression in immunodeficient mice and bioluminescence imaging Procedures were performed with approved protocols, in accordance with the Ethics Committee for Animal Experimentation' of the Instituto de Salud Carlos III (ISCIII), EU commission regulations for laboratory animals' care.
